Analysts offer commentary on cannabinoid pharmaceutical company GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) and biopharm firm Relypsa Inc (NASDAQ:RLYP) with differing opinions. One analyst sings GWPH’s …
Healthcare analysts weighed in with a few insights on Canadian drug maker Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and US biotech firm Relypsa Inc (NASDAQ:RLYP). The analysts …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2015 and announced other corporate …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced that on February 16, 2016, the compensation committee of the company’s board of directors granted …
Healthcare analysts weighed in today on biotech companies Relypsa Inc (NASDAQ:RLYP) and Inovio Pharmaceuticals Inc (NASDAQ:INO), as Relypsa gained Medicare coverage for Veltassa, …
Healthcare analysts weighed in today on small biopharmaceutical firms Relypsa Inc (NASDAQ:RLYP) and Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), following meeting with management and Phase II clinical trial …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, announced that on February 1, 2016, the compensation committee of the company’s board of directors granted 10 …
Healthcare analysts provided insight on both Relypsa Inc (NASDAQ:RLYP) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) with bullish outlooks.
Healthcare analysts weighed in today with positive reports on biopharmaceutical companies Relypsa Inc (NASDAQ:RLYP) and Keryx Biopharmaceuticals (NASDAQ:KERX). The analysts reflect on Relypsa’s positive results from Veltassa’s …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced results from 12 Phase 1 studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa® (patiromer) …
